Mr. Enright is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Mr. Enright began his investment career at PaineWebber Development Corporation. Mr. Enright also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the board of directors of BioAge Labs, Inc., and Zenas Biopharma, Inc. as well as several private companies, including as Chair of CuraSen Therapeutics, Inc.
Selected prior public company board memberships include Aptinyx Inc., Aimmune Therapeutics, Inc., (acquired by Nestlé Health Science in October 2020), Codexis, Inc., Corcept Therapeutics, Inc., Esperion Therapeutics, Inc., Horizon Pharma plc and Threshold Pharmaceuticals, Inc. Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.
What is Patrick G. Enright's net worth?
The estimated net worth of Patrick G. Enright is at least $298.60 thousand as of December 11th, 2025. Mr. Enright owns 5,882 shares of Vera Therapeutics stock worth more than $298,600 as of December 19th. This net worth estimate does not reflect any other assets that Mr. Enright may own. Learn More about Patrick G. Enright's net worth.
How do I contact Patrick G. Enright?
Has Patrick G. Enright been buying or selling shares of Vera Therapeutics?
During the last ninety days, Patrick G. Enright has bought $249,985.00 in Vera Therapeutics stock. Most recently, on Thursday, December 11th, Patrick G. Enright bought 5,882 shares of Vera Therapeutics stock. The stock was acquired at an average cost of $42.50 per share, with a total value of $249,985.00. Following the completion of the transaction, the director now directly owns 5,882 shares of the company's stock, valued at $249,985. Learn More on Patrick G. Enright's trading history.
Who are Vera Therapeutics' active insiders?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, Vera Therapeutics insiders bought shares 3 times. They purchased a total of 255,882 shares worth more than $5,527,583.36. In the last year, insiders at the sold shares 2 times. They sold a total of 32,500 shares worth more than $1,166,350.00. The most recent insider tranaction occured on December, 11th when Director Patrick G Enright bought 5,882 shares worth more than $249,985.00. Insiders at Vera Therapeutics own 16.3% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 12/11/2025.
